EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches

Shiqi Lu, Lunbiao Gan, Tong Lu, Keying Zhang, Jiayu Zhang, Xinjie Wu, Donghui Han, Chao Xu, Shaojie Liu, Fa Yang, Weijun Qin, Weihong Wen

Theranostics · 2024 · 14 (1) · 379-391

DOI: 10.7150/thno.89495 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Shiqi Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi 710…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endosialin, also known as tumor endothelial marker 1 (TEM1) or CD248, is a single transmembrane glycoprotein with a C-type lectin-like domain. Endosialin is mainly expressed in the stroma, especially in cancer-associated fibroblasts and pericytes, in most solid tumors. Endosialin is also expressed in tumor cells of most sarcomas. Endosialin can promote tumor progression through different mechanisms, such as promoting tumor cell proliferation, adhesion and migration, stimulating tumor angiogenesis, and inducing an immunosuppressive tumor microenvironment. Thus, it is considered an ideal target for cancer treatment. Several endosialin-targeted antibodies and therapeutic strategies have been developed and have shown preliminary antitumor effects. Here, we reviewed the endosialin expression pattern in different cancer types, discussed the mechanisms by which endosialin promotes tumor progression, and summarized current therapeutic strategies targeting endosialin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasmsHumansNeovascularization, PathologicPericytesTumor MicroenvironmentAntigens, CD

Stichwörter der Autor:innen

CD248TEM1angiogenesisendosialintargeted therapytumor microenvironmenttumor progression

Substanzen

Antigens, NeoplasmCD248 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, Shaanxi 710072, China.
  • Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.

Zitieren

APA

Lu, S., Gan, L., Lu, T., Zhang, K., Zhang, J., Wu, X., Han, D., Xu, C., Liu, S., Yang, F., Qin, W., & Wen, W. (2024). Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics, 14(1), 379-391. https://doi.org/10.7150/thno.89495

Vancouver

Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, et al. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Theranostics. 2024;14(1):379-391. doi:10.7150/thno.89495

BibTeX
@article{Lu2024,
  author = {Lu, Shiqi and Gan, Lunbiao and Lu, Tong and Zhang, Keying and Zhang, Jiayu and Wu, Xinjie and Han, Donghui and Xu, Chao and Liu, Shaojie and Yang, Fa and Qin, Weijun and Wen, Weihong},
  title = {Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches},
  journal = {Theranostics},
  year = {2024},
  volume = {14},
  number = {1},
  pages = {379--391},
  doi = {10.7150/thno.89495}
}
Kostenlos starten →